Cristina Martín-Lorente

447 total citations · 1 hit paper
15 papers, 279 citations indexed

About

Cristina Martín-Lorente is a scholar working on Oncology, Reproductive Medicine and Immunology. According to data from OpenAlex, Cristina Martín-Lorente has authored 15 papers receiving a total of 279 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 10 papers in Reproductive Medicine and 4 papers in Immunology. Recurrent topics in Cristina Martín-Lorente's work include Ovarian cancer diagnosis and treatment (10 papers), PARP inhibition in cancer therapy (8 papers) and BRCA gene mutations in cancer (3 papers). Cristina Martín-Lorente is often cited by papers focused on Ovarian cancer diagnosis and treatment (10 papers), PARP inhibition in cancer therapy (8 papers) and BRCA gene mutations in cancer (3 papers). Cristina Martín-Lorente collaborates with scholars based in Spain, Canada and United States. Cristina Martín-Lorente's co-authors include María Rodríguez Gámez, Josep Balart, Francisco Rodríguez, María Virtudes Céspedes, José Luís Corchero, Raúl Ruiz, Ramón Rovira, Elisa Llurba, José Alejandro Pérez Fidalgo and Maria-Pilar Barretina-Ginesta and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Biomolecules.

In The Last Decade

Cristina Martín-Lorente

14 papers receiving 276 citations

Hit Papers

Nano-Based Approved Pharmaceuticals for Cancer Treatment:... 2022 2026 2023 2024 2022 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges
    2022 169 citations Francisco Rodríguez, María Rodríguez Gámez et al. Biomolecules profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Cristina Martín-Lorente Spain 6 90 89 87 80 58 15 279
Shu Yao China 12 49 0.5× 93 1.0× 63 0.7× 147 1.8× 70 1.2× 17 432
Elizaveta Reznichenko United States 3 42 0.5× 101 1.1× 85 1.0× 135 1.7× 15 0.3× 5 259
Mahdieh Shokrollahi Barough Iran 11 44 0.5× 74 0.8× 80 0.9× 125 1.6× 16 0.3× 31 326
Aaron J. Sorrin United States 7 116 1.3× 56 0.6× 152 1.7× 181 2.3× 44 0.8× 9 456
Bárbara Mesquita Portugal 12 83 0.9× 74 0.8× 83 1.0× 141 1.8× 9 0.2× 17 324
Eloy Yinwang China 12 29 0.3× 75 0.8× 129 1.5× 137 1.7× 17 0.3× 23 397
Tankut G. Güney United Kingdom 6 21 0.2× 88 1.0× 67 0.8× 147 1.8× 39 0.7× 7 318
Daniela Burgos-Ojeda United States 5 46 0.5× 207 2.3× 58 0.7× 199 2.5× 82 1.4× 5 368
Yun‐Long Tseng Taiwan 10 166 1.8× 100 1.1× 76 0.9× 186 2.3× 10 0.2× 14 357
Nasim Kheshtchin Iran 9 56 0.6× 151 1.7× 96 1.1× 189 2.4× 18 0.3× 16 479

Countries citing papers authored by Cristina Martín-Lorente

Since Specialization
Citations

This map shows the geographic impact of Cristina Martín-Lorente's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cristina Martín-Lorente with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cristina Martín-Lorente more than expected).

Fields of papers citing papers by Cristina Martín-Lorente

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cristina Martín-Lorente. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cristina Martín-Lorente. The network helps show where Cristina Martín-Lorente may publish in the future.

Co-authorship network of co-authors of Cristina Martín-Lorente

This figure shows the co-authorship network connecting the top 25 collaborators of Cristina Martín-Lorente. A scholar is included among the top collaborators of Cristina Martín-Lorente based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cristina Martín-Lorente. Cristina Martín-Lorente is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Gallego, Alejandro, Ainhoa Madariaga, Anna Carbó, et al.. (2025). An ambispective, real-world multi-center study of DOstarlimab in patients with Recurrent or Advanced DNA mismatch repair deficient/microsatellite instability-high endometrial cancer (GEICO 120-R/DORA study). International Journal of Gynecological Cancer. 35(7). 101903–101903.
2.
Fidalgo, José Alejandro Pérez, Fernando Gálvez, Ainhoa Madariaga, et al.. (2024). SEOM–GEICO clinical guideline on epithelial ovarian cancer (2023). Clinical & Translational Oncology. 26(11). 2758–2770. 7 indexed citations
3.
4.
5.
Rodríguez, Francisco, María Rodríguez Gámez, Josep Balart, et al.. (2022). Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges. Biomolecules. 12(6). 784–784. 169 indexed citations breakdown →
6.
Labidi‐Galy, Sana Intidhar, Manuel Rodrigues, José Luís Sandoval, et al.. (2022). Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis. Annals of Oncology. 34(2). 152–162. 27 indexed citations
7.
Friedländer, Michael, Val Gebski, Andrew R. Clamp, et al.. (2022). The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer. Annals of Oncology. 33(6). 593–601. 16 indexed citations
8.
Labidi‐Galy, Sana Intidhar, Manuel Rodrigues, José Luís Sandoval, et al.. (2022). Efficacy of maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced ovarian cancer according to BRCA mutation genotype in the phase III PAOLA-1/ENGOT-ov25 trial.. Journal of Clinical Oncology. 40(16_suppl). 5571–5571. 2 indexed citations
9.
Palacio, Isabel, Cristina Churruca, Beatriz Pardo, et al.. (2021). 674 Niraparib as maintenance therapy in platinum-sensitive recurrent ovarian cancer: a GEICO study within the Spanish extended access program. A261.1–A261. 1 indexed citations
10.
Redondo, Andrés, E.M. Guerra, Luís Manso, et al.. (2021). SEOM clinical guideline in ovarian cancer (2020). Clinical & Translational Oncology. 23(5). 961–968. 29 indexed citations
11.
Redondo, Andrés, Ana Oaknin, María Jesús Rubio, et al.. (2021). Management of advanced ovarian cancer in Spain: an expert Delphi consensus. Journal of Ovarian Research. 14(1). 72–72. 1 indexed citations
12.
13.
Lheureux, Stéphanie, Marcus O. Butler, Gini F. Fleming, et al.. (2014). A Phase 1/2 Study of Ipilimumab in Women with Metastatic or Recurrent Hpv-Related Cervical Carcinoma: a Study of the Princess Margaret and Chicago N01 Consortia. Annals of Oncology. 25. iv324–iv324. 2 indexed citations
14.
Martín-Lorente, Cristina, David S.P. Tan, Neesha C. Dhani, et al.. (2014). Phase II study of oral ENMD-2076 administered to patients with ovarian clear cell carcinoma: A trial of the Princess Margaret Phase II Consortium.. Journal of Clinical Oncology. 32(15_suppl). TPS5620–TPS5620. 2 indexed citations
15.
Lheureux, Stéphanie, Marcus O. Butler, Gini F. Fleming, et al.. (2014). A phase 1/2 study of ipilimumab in women with metastatic or recurrent HPV-related cervical carcinoma: A study of the Princess Margaret and Chicago N01 Consortia.. Journal of Clinical Oncology. 32(15_suppl). TPS5631–TPS5631. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shu Yao Breakdown of academic impact, for papers by Elizaveta Reznichenko Breakdown of academic impact, for papers by Mahdieh Shokrollahi Barough Breakdown of academic impact, for papers by Aaron J. Sorrin Breakdown of academic impact, for papers by Bárbara Mesquita Breakdown of academic impact, for papers by Eloy Yinwang Breakdown of academic impact, for papers by Tankut G. Güney Breakdown of academic impact, for papers by Daniela Burgos-Ojeda Breakdown of academic impact, for papers by Yun‐Long Tseng Breakdown of academic impact, for papers by Nasim Kheshtchin
Rankless by CCL
2026